How Does Logynon Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Logynon Works
- Active ingredients: Ethinylestradiol (oestrogen) and levonorgestrel (progestogen) in a triphasic regimen (three different dose combinations).
- Primary actions: Prevents ovulation, thickens cervical mucus to block sperm, and alters the endometrium to discourage implantation.
- Onset & duration: Immediate contraceptive effect if started on day 1 of cycle; 21‑day active pills followed by 7 pill‑free days.
- Metabolism: Both hormones are metabolised in the liver (mainly CYP3A4) and excreted in urine and faeces.
- Effectiveness: >99% effective with perfect use; also provides non‑contraceptive benefits (lighter periods, reduced menstrual pain).
Logynon is a triphasic combined oral contraceptive that delivers a carefully phased combination of oestrogen and progestogen to mimic the natural menstrual cycle while providing reliable contraception. This guide explains the precise pharmacological actions that make it effective.
Important Medical Advice
Seek urgent medical attention if you experience sudden swelling or pain in a leg, unexplained breathlessness, chest pain, severe headache, or sudden vision changes — these could be signs of a blood clot (deep vein thrombosis, pulmonary embolism, or stroke). Combined hormonal contraceptives like Logynon slightly increase the risk of thrombosis.
Chemical Composition & Molecular Structure
Logynon is a triphasic combined oral contraceptive containing two active substances: ethinylestradiol (a synthetic oestrogen) and levonorgestrel (a second‑generation progestogen). The tablets are sugar‑coated and presented in three colour‑coded phases:
- 6 light brown tablets: 50 µg levonorgestrel + 30 µg ethinylestradiol
- 5 white tablets: 75 µg levonorgestrel + 40 µg ethinylestradiol
- 10 ochre tablets: 125 µg levonorgestrel + 30 µg ethinylestradiol
Excipients include lactose, sucrose, maize starch, povidone, magnesium stearate, macrogol 6000, calcium carbonate, talc, glycol montanate, glycerin, titanium dioxide, and iron oxides (E172).
Structural details
17α‑ethinylestradiol; a synthetic derivative of oestradiol with an ethinyl group at C17, which slows hepatic metabolism and enhances oral bioavailability.
Levonorgestrel is a second‑generation progestogen, the biologically active enantiomer of norgestrel. It has high affinity for progesterone receptors and minimal androgenic activity compared to older progestins.
| Property | Ethinylestradiol | Levonorgestrel |
|---|---|---|
| Lipophilicity (logP) | 3.67 | 3.8 |
| Protein binding | ~98% (albumin, induces SHBG) | 97‑99% (SHBG, albumin) |
| Oral bioavailability | ~45% (first‑pass) | ~100% |
| Receptor affinity | Oestrogen receptor α/β agonist | Progesterone receptor agonist |
🗒️ Pharmaceutical insight: The triphasic design reduces total hormone exposure while maintaining cycle control, closely imitating the natural hormonal fluctuations of the menstrual cycle.
Mechanism of Action: How Logynon Prevents Pregnancy
Logynon employs three complementary mechanisms to provide effective contraception:
- Ovulation inhibition: The combination of ethinylestradiol and levonorgestrel suppresses the hypothalamic‑pituitary‑ovarian axis. Ethinylestradiol reduces FSH secretion, preventing follicle selection; levonorgestrel blunts the LH surge, thereby blocking ovulation.
- Cervical mucus thickening: Levonorgestrel increases the viscosity of cervical mucus, making it impenetrable to sperm throughout the cycle.
- Endometrial alteration: The progestogen‑dominant effect renders the endometrium thin, atrophic, and unreceptive to implantation, providing a third layer of protection.
| Target tissue | Hormone responsible | Effect |
|---|---|---|
| Hypothalamus/pituitary | Both | Suppression of gonadotropin release |
| Cervix | Levonorgestrel | Mucus thickening |
| Endometrium | Levonorgestrel | Atrophy, glandular regression |
Absorption & Distribution (Pharmacokinetics)
After oral administration, both hormones are rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations occur within 1‑2 hours for levonorgestrel and 1‑2 hours for ethinylestradiol.
Distribution
Levonorgestrel is highly bound to sex hormone‑binding globulin (SHBG) and albumin; ethinylestradiol binds to albumin and induces hepatic synthesis of SHBG, which can increase levonorgestrel binding over time.
Steady state
Due to the triphasic dosing, serum levels of both hormones rise progressively during each 21‑day cycle, with levonorgestrel accumulation influenced by SHBG induction.
Metabolic Effects & Elimination
Ethinylestradiol undergoes extensive first‑pass metabolism in the liver: it is primarily oxidised by CYP3A4 to 2‑hydroxyethinylestradiol, then conjugated to glucuronides and sulfates. Enterohepatic recirculation occurs. Elimination half‑life is 10‑20 hours; metabolites are excreted in urine (60%) and faeces (40%).
Levonorgestrel is metabolised via reduction of the Δ4‑3‑oxo group and hydroxylation, followed by conjugation. It is not subject to significant first‑pass effect. Half‑life is approximately 20‑30 hours. Excretion is primarily renal (as metabolites) with some biliary elimination.
⚠️ Metabolic caution: Drugs that induce CYP3A4 (e.g., rifampicin, certain anticonvulsants, St John’s wort) can accelerate hormone metabolism and reduce contraceptive efficacy. Always check for interactions.
Clinical Efficacy & Benefits
When taken correctly (without missed pills), Logynon has a Pearl Index of approximately 0.3 (pregnancy rate per 100 woman‑years). With typical use, effectiveness is around 91‑92%. Beyond contraception, Logynon offers several non‑contraceptive advantages:
- More regular, lighter, and less painful periods
- Reduction in premenstrual symptoms
- Lower risk of ovarian and endometrial cancer with long‑term use
- Possible improvement in acne (due to increased SHBG reducing free testosterone)
It does not protect against sexually transmitted infections — condom use is recommended when STI risk exists.
Logynon FAQs
What should I do if I miss a Logynon pill?
If you are less than 12 hours late, take the missed pill immediately and continue as usual. If more than 12 hours late, contraceptive protection may be reduced; follow the missed pill instructions in the leaflet and use extra precautions (e.g., condoms) for 7 days.
Can Logynon cause weight gain?
Some women report mild fluid retention or appetite changes, but large studies show no consistent link between modern low‑dose pills like Logynon and significant weight gain.
How soon after starting Logynon am I protected?
If you start on the first day of your period, protection is immediate. If started on another day, use additional contraception (e.g., condoms) for the first 7 days.
Does Logynon increase the risk of blood clots?
Yes, combined pills slightly increase the risk of venous thromboembolism compared to non‑users. For Logynon (containing levonorgestrel), the risk is about 5‑7 per 10,000 women per year — lower than with some newer progestogens.
Can I take Logynon while breastfeeding?
Generally not recommended because oestrogen can reduce milk supply. Your doctor can advise on progestogen‑only options suitable during breastfeeding.
Need Logynon with Expert Guidance?
If you’re considering Logynon or any combined contraceptive pill, a UK‑registered doctor can review your medical history and help you choose the right method.
Secure Prescription & Next‑Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Contraception ConsultationRelated Logynon Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 27 March 2026
Next Review: 27 September 2026
Published on: 27 March 2026
Last Updated: 27 March 2026